Posts

The Day AI Made Me Rethink What Science Could Do

The Day AI Made Me Rethink What Science Could Do
halesmi2

/by
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi

Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
weberfr8

/by
Fortune includes Novartis in 2026 Change The World List for malaria program

Fortune includes Novartis in 2026 Change The World List for malaria program
tavasat1

/by
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
/by
American Chemical Society honors Novartis researchers

American Chemical Society honors Novartis researchers
halesmi2

/by
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR
   

/by
25 years of expanding access to cancer care

25 years of expanding access to cancer care
tavasat1

/by
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis

  • Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals
  • New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in patients with atrial fibrillation, including recurrent bleeding events
  • Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice
/by